AR070033A1 - INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES - Google Patents
INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USESInfo
- Publication number
- AR070033A1 AR070033A1 ARP080104860A ARP080104860A AR070033A1 AR 070033 A1 AR070033 A1 AR 070033A1 AR P080104860 A ARP080104860 A AR P080104860A AR P080104860 A ARP080104860 A AR P080104860A AR 070033 A1 AR070033 A1 AR 070033A1
- Authority
- AR
- Argentina
- Prior art keywords
- biocompatible
- composition
- optionally
- polymer
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Se proveen composiciones inyectables que comprenden al menos un agente activo seleccionado de un grupo que incluye antipsicoticos, inhibidores de aromatasa, agentes bloqueantes adrenérgicos alfa-1, inhibidores de acetilcolinesterasa o sales farmacéuticamente aceptables, derivados, isomeros, polimorfos, solvatos, hidratos, análogos, enantiomeros, formas tautoméricas o mezclas de los mismos; al menos un polímero bioerosionable biocompatible; al menos un solvente no toxico biocompatible y opcionalmente uno o más excipientes farmacéuticamente aceptables. La presente también describe el proceso para la preparacion de tales composiciones y el método para su utilizacion. Reivindicacion 2: Una composicion tal como se reivindica en la reivindicacion 1, caracterizada porque la composicion comprende como agente activo al menos un antipsicotico, preferentemente ziprasidona u olanzapina o aripiprazol, o al menos un inhibidor de aromatasa preferentemente anastrozol o letrozol, o al menos un agente bloqueante adrenérgico preferentemente tamsulosina o al menos un inhibidor de acetilcolinesterasa preferentemente donepezil, o sales farmacéuticamente aceptables, derivados, isomeros, polimorfos, solvatos, hidratos, análogos, enantiomeros, formas tautoméricas o sus mezclas; al menos un polímero bioerosionable biocompatible; al menos un solvente no toxico biocompatible y opcionalmente uno o más excipientes farmacéuticamente aceptables, las cuales están en forma de una composicion gelificante in situ o una composicion de implante y que forman un deposito luego de la administracion in vivo y del contacto con los fluidos corporales con lo cual se provee una liberacion prolongada del agente activo durante períodos prolongados de tiempo. Reivindicacion 7: Una composicion tal como se reivindica en la reivindicacion 6, caracterizado porque el polímero basado en ácido glicolico o láctico es un polímero poliláctido (PLA) o un polímero poliglicolido o un copolímero poli(láctido-co-glicolido) (PLGA). Reivindicacion 8: La composicion tal como se reivindica en cualquiera de las reivindicaciones precedentes 1 a 7, caracterizada porque la composicion provee una composicion gelificante in situ que comprende el agente activo y preferentemente un polímero PLGA, disuelto o disperso o suspendido en un solvente adecuado opcionalmente disuelto o dispersado o suspendido adicionalmente en un diluyente líquido tal como un vehículo acuoso o un solvente orgánico o un vehículo oleoso. Reivindicacion 22: La composicion tal como se reivindica en cualquiera de las reivindicaciones 1 a 21, caracterizada porque el solvente no toxico biocompatible se selecciona de un grupo que comprende triacetina, etanol, bencil alcohol, 1-butano!, 2-butanol, cloroformo, ácido acético, alcohol isopropílico, acetonitrilo, N-metil-2-pirrolidona (NMP), 2-pirrolidona, migliol, glicerol, acetato de metilo, metil isobutil cetona, benzoato de bencilo, propilenglicol, dimetil isosorbida, propilen carbonato, etil acetato, etil lactato, dimetil sulfona, N,N-dietil-m-toluamida, metil etil cetona, dimetilformamida, diclorometano, benzonitrilo, dimetil isosorbida, dimetil sulfoxida, ácido oleico y 1-dodecilazaciclo-heptan-2-ona y similares o sus mezclas. Reivindicacion 36: Un kit farmacéutico adecuado para la formacion in situ de un implante o gel de deposito biodegradable a partir de las composiciones tal como se reivindican en la reivindicacion 1, en el cuerpo de un sujeto que lo necesita, caracterizado porque comprende un dispositivo que contiene ziprasidona u olanzapina o aripiprazol o anastrozol o letrozol o tamsulosina o donepezil corno agente activo, opcionalmente al menos un polímero bioerosionable biocompatible y opcionalmente uno o más excipientes farmacéuticamente aceptables; y un dispositivo que contiene al menos un solvente no toxico biocompatible, opcionalmente al menos un polímero bioerosionable biocompatible y opcionalmente uno o más excipientes farmacéuticamente aceptables; en donde los dispositivos permiten la expulsion de los contenidos de los dos dispositivos para permitir su mezcla antes de administrar el contenido en el cuerpo de un sujeto que lo necesite. Reivindicacion 51: El uso de la composicion de acuerdo con la reivindicacion 1, caracterizado porque comprende ziprasidona u olanzapina o aripiprazol como agente activo para la fabricacion de un medicamento para la profilaxis, mejora y/o el tratamiento de los signos y los síntomas de esquizofrenia.Injectable compositions are provided comprising at least one active agent selected from a group that includes antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogs, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible biocompatible polymer; at least one non-toxic biocompatible solvent and optionally one or more pharmaceutically acceptable excipients. The present also describes the process for the preparation of such compositions and the method for their use. Claim 2: A composition as claimed in claim 1, characterized in that the composition comprises as active agent at least one antipsychotic, preferably ziprasidone or olanzapine or aripiprazole, or at least one aromatase inhibitor preferably anastrozole or letrozole, or at least one adrenergic blocking agent preferably tamsulosin or at least one acetylcholinesterase inhibitor preferably donepezil, or pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogs, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible biocompatible polymer; at least one biocompatible non-toxic solvent and optionally one or more pharmaceutically acceptable excipients, which are in the form of an in situ gelling composition or an implant composition and which form a reservoir after in vivo administration and contact with body fluids thereby providing a prolonged release of the active agent for extended periods of time. Claim 7: A composition as claimed in claim 6, characterized in that the glycolic or lactic acid based polymer is a polylactide polymer (PLA) or a polyglycolide polymer or a poly (lactide-co-glycolide) copolymer (PLGA). Claim 8: The composition as claimed in any one of the preceding claims 1 to 7, characterized in that the composition provides an in situ gelling composition comprising the active agent and preferably a PLGA polymer, dissolved or dispersed or suspended in a suitable solvent optionally dissolved or dispersed or suspended further in a liquid diluent such as an aqueous vehicle or an organic solvent or an oily vehicle. Claim 22: The composition as claimed in any one of claims 1 to 21, characterized in that the biocompatible non-toxic solvent is selected from a group comprising triacetin, ethanol, benzyl alcohol, 1-butane !, 2-butanol, chloroform, acetic acid, isopropyl alcohol, acetonitrile, N-methyl-2-pyrrolidone (NMP), 2-pyrrolidone, migliol, glycerol, methyl acetate, methyl isobutyl ketone, benzyl benzoate, propylene glycol, dimethyl isosorbide, propylene carbonate, ethyl acetate, ethyl lactate, dimethyl sulfone, N, N-diethyl-m-toluamide, methyl ethyl ketone, dimethylformamide, dichloromethane, benzonitrile, dimethyl isosorbide, dimethyl sulfoxide, oleic acid and 1-dodecylazacyclo-heptan-2-one and the like or mixtures thereof. Claim 36: A pharmaceutical kit suitable for the in situ formation of a biodegradable deposit implant or gel from the compositions as claimed in claim 1, in the body of a subject in need thereof, characterized in that it comprises a device that contains ziprasidone or olanzapine or aripiprazole or anastrozole or letrozole or tamsulosin or donepezil as an active agent, optionally at least one biocompatible bioerodible polymer and optionally one or more pharmaceutically acceptable excipients; and a device containing at least one biocompatible non-toxic solvent, optionally at least one biocompatible bioerodible polymer and optionally one or more pharmaceutically acceptable excipients; where the devices allow the expulsion of the contents of the two devices to allow their mixing before administering the content in the body of a subject that needs it. Claim 51: The use of the composition according to claim 1, characterized in that it comprises ziprasidone or olanzapine or aripiprazole as an active agent for the manufacture of a medicament for the prophylaxis, improvement and / or treatment of the signs and symptoms of schizophrenia .
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2321DE2007 | 2007-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070033A1 true AR070033A1 (en) | 2010-03-10 |
Family
ID=40626309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104860A AR070033A1 (en) | 2007-11-06 | 2008-11-06 | INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR070033A1 (en) |
| CL (1) | CL2008003305A1 (en) |
| WO (1) | WO2009060473A2 (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2526996T3 (en) | 2002-12-20 | 2019-12-02 | Xeris Pharmaceuticals Inc | Formulation for intracutaneous injection |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| ES2390439B1 (en) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | INJECTABLE COMPOSITION |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| ES2589106T3 (en) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Injection controlled antipsychotic composition |
| PL2394663T3 (en) * | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Compositions for injectable in-situ biodegradable implants |
| WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
| US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
| CA2816203C (en) * | 2010-10-28 | 2017-02-21 | Transdermal Research Pharm Laboratories, Llc | Aripiprazole compositions and methods for its transdermal delivery |
| PL3257498T3 (en) | 2010-12-29 | 2020-02-28 | Medincell | Biodegradable drug delivery compositions |
| BR112013023062B1 (en) | 2011-03-10 | 2022-01-18 | Xeris Pharmaceuticals, Inc | STABLE SOLUTION FOR PARENTERAL INJECTION AND MANUFACTURING METHOD OF IT |
| EP4327872A2 (en) | 2011-03-18 | 2024-02-28 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| TWI583401B (en) | 2011-10-24 | 2017-05-21 | 布雷本製藥股份有限公司 | Implantable tizanidine compositions and methods of treatment thereof |
| CA2853277A1 (en) * | 2011-10-24 | 2013-05-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions and methods of treatment thereof |
| KR102007057B1 (en) | 2011-10-31 | 2019-08-02 | 엑스에리스 파머수티클스, 인크. | Formulations for the treatment of diabetes |
| ES2765036T3 (en) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| ES2950418T3 (en) * | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
| ES2764383T3 (en) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| US20160022571A1 (en) * | 2013-03-14 | 2016-01-28 | Braeburn Pharmaceuticals Bvba Sprl | Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof |
| US9452131B2 (en) | 2014-03-20 | 2016-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| EP3871709A1 (en) | 2014-08-06 | 2021-09-01 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| CN104189954B (en) * | 2014-09-19 | 2017-03-29 | 中国科学院长春应用化学研究所 | A kind of in-situ solidifying tissue engineering bracket and preparation method thereof |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| TWI718168B (en) * | 2015-08-03 | 2021-02-11 | 愛爾蘭商托爾瑪國際有限公司 | Liquid polymer delivery system for extended administration of drugs |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| KR20180091016A (en) | 2015-11-16 | 2018-08-14 | 메딘셀 | A method for micellising and / or targeting an active ingredient that is pharmaceutically active in synovial tissue |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| KR102033686B1 (en) * | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | Microneedle transdermal patch comprising donepezil |
| AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| GB2568526A (en) * | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
| US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| PE20210047A1 (en) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | INJECTABLE COMPOSITION |
| AU2019348739A1 (en) * | 2018-09-25 | 2021-04-22 | Tolmar International, Ltd. | Liquid polymer delivery system for extended administration of drugs |
| US11911499B2 (en) * | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| CN113209370B (en) * | 2020-01-21 | 2023-11-28 | 渼颜空间(河北)生物科技有限公司 | Biodegradable injection filler, preparation method and application thereof |
| WO2023278695A1 (en) * | 2021-06-30 | 2023-01-05 | The University Of North Carolina At Chapel Hill | Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery |
| WO2023116517A1 (en) * | 2021-12-24 | 2023-06-29 | 四川科伦药物研究院有限公司 | Continuous delivery preparation capable of being stably released and preparation method therefor |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
| US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2275587C (en) * | 1996-12-20 | 2006-10-24 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
| US7128927B1 (en) * | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US20030049320A1 (en) * | 2000-12-18 | 2003-03-13 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
| CA2586846C (en) * | 2004-11-10 | 2013-12-31 | Qlt Usa Inc. | A stabilized polymeric delivery system |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| CN101541313A (en) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | Novel injectable depot compositions and process of preparation of such compositions |
-
2008
- 2008-11-06 AR ARP080104860A patent/AR070033A1/en unknown
- 2008-11-06 CL CL2008003305A patent/CL2008003305A1/en unknown
- 2008-11-06 WO PCT/IN2008/000757 patent/WO2009060473A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008003305A1 (en) | 2009-06-05 |
| WO2009060473A2 (en) | 2009-05-14 |
| WO2009060473A3 (en) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070033A1 (en) | INJECTABLE COMPOSITIONS, THEIR PROCESSES AND USES | |
| AR063120A1 (en) | INJECTABLE DEPOSIT COMPOSITIONS AND PROCESS TO PREPARE THEM | |
| EP2387394B1 (en) | Transdermal administration of tamsulosin | |
| ES2637447T3 (en) | Topical formulations containing a steroid | |
| JP5635075B2 (en) | Antifungal pharmaceutical composition | |
| ES2767251T3 (en) | Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility | |
| PE20060244A1 (en) | PHARMACEUTICAL DEPOSIT FORMULATION CONTAINING POLYETHYLENE GLYCOL OF MOLECULAR WEIGHT LESS THAN 600 DALTONS | |
| JP2008530127A (en) | Formulation for eye treatment | |
| CN101400348A (en) | Tetrahydroisoquinoline derivatives to enhance memory function | |
| WO2009008487A1 (en) | Coated preparation | |
| CA2468703A1 (en) | Controlled release polymeric compositions of bone growth promoting compounds | |
| AU2011320758B2 (en) | Aripiprazole compositions and methods for its transdermal delivery | |
| BR112020005948A2 (en) | intensified distribution of epinephrine and prodrug compositions | |
| CA2762770A1 (en) | Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing | |
| AR052155A1 (en) | ORGANIC COMPOUNDS | |
| US9731026B2 (en) | Neat liquid pharmaceutical formulations | |
| PE20020833A1 (en) | CHEMOTHERAPIC COMPOSITIONS OF PACLITAXEL IN MICROEMULSION WITH GREATER ORAL BIOAVAILABILITY | |
| BR112012015437A2 (en) | substantially anhydrous stable storage topical composition | |
| WO2013081014A1 (en) | Adhesive skin patch | |
| AR085273A1 (en) | PROPELLENT FREE LIQUID FORMULATION THAT INCLUDES AN ANTIMUSCARINIC DRUG | |
| CN106068122A (en) | The stabilization method of dibenzylatiooluene | |
| EP1011647A1 (en) | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith | |
| TW200819442A (en) | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy | |
| BR112019021807A2 (en) | plaster containing rupatadine | |
| TW201637648A (en) | Drug delivery system targeting lacrimal gland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |